Ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

BACKGROUND: Ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), is an effective therapy for patients with relapsed chronic lymphocytic leukemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab (iR)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Burger, Jan A., Keating, Michael J., Wierda, William G., Hartmann, Elena, Hoellenriegel, Julia, Rosin, Nathalie Y., de Weerdt, Iris, Jeyakumar, Ghayathri, Ferrajoli, Alessandra, Cardenas-Turanzas, Marylou, Lerner, Susan, Jorgensen, Jeffrey L, Nogueras-González, Graciela M., Zacharian, Gracy, Huang, Xuelin, Kantarjian, Hagop, Garg, Naveen, Rosenwald, Andreas, O’Brien, Susan
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4174348/
https://ncbi.nlm.nih.gov/pubmed/25150798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70335-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados